索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]任昌振,董士铭,胡博文,等.射血分数保留型心力衰竭与冠状动脉微循环障碍[J].国际心血管病杂志,2021,01:1-4.
点击复制

射血分数保留型心力衰竭与冠状动脉微循环障碍(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2021年01期
页码:
1-4
栏目:
综述
出版日期:
2021-01-20

文章信息/Info

Title:
-
作者:
任昌振; 董士铭; 胡博文; 杨本钊; 张艳达; 贺治青; 梁春
200003 上海,海军军医大学附属长征医院心血管内科
Author(s):
-
关键词:
心力衰竭;  射血分数保留;  冠状动脉微循环障碍
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2021.01.001
文献标识码:
-
摘要:
射血分数保留型心力衰竭(HFpEF)是一种复杂的临床综合征,因其发病机制不清,目前尚无有效改善预后的治疗手段。证据表明,多重共病继发的冠状动脉微循环障碍(CMD)可能是导致HFpEF的重要致病机制之一。该文就HFpEF发生发展中CMD致心肌缺血、心肌纤维化等作用机制,以及HFpEF治疗策略中以CMD为新靶点的探索作简要阐述.
Abstract:
-

参考文献/References

[1] Thomson LE, Wei J, Agarwal M, et al. Cardiac magnetic resonance myocardial perfusion reserve index is reduced in women with coronary microvascular dysfunction. A National Heart, Lung, and Blood Institute-sponsored study from the women’s ischemia syndrome evaluation[J]. Circ Cardiovasc Imaging, 2015, 8(4):10.
[2] Bakir M, Nelson MD, Jones E, et al. Heart failure hospitalization in women with signs and symptoms of ischemia: a report from the women’s ischemia syndrome evaluation study[J]. Int J Cardiol, 2016, 223:936-939.
[3] Shah SJ, Lam CSP, Svedlund S, et al. Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF[J]. Eur Heart J, 2018, 39(37):3439-3450.
[4] Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC)developed with the special contribution of the Heart Failure Association(HFA)of the ESC[J]. Eur Heart J, 2016, 37(27):2129-2200.
[5] Chioncel O, Lainscak M, Seferovic PM, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC heart failure long-term registry[J]. Eur J Heart Fail, 2017, 19(12):1574-1585.
[6] Dunlay SM, Roger VL,Redfield MM. Epidemiology of heart failure with preserved ejection fraction[J]. Nat Rev Cardiol, 2017,14(10):591-602.
[7] Shah KS, Xu H, Matsouaka RA, et al. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes[J]. J Am Coll Cardiol, 2017, 70(20):2476-2486.
[8] Vaduganathan M, Patel RB, Michel A, et al. Mode of death in heart failure with preserved ejection fraction[J]. J Am Coll Cardiol, 2017, 69(5):556-569.
[9] Badimon L, Bugiardini R, Cenko E, et al. Position paper of the European Society of Cardiology-working group of coronary pathophysiology and microcirculation: obesity and heart disease[J]. Eur Heart J, 2017, 38(25):1951-1958.
[10] Camici PG, d’Amati G, Rimoldi O. Coronary microvascular dysfunction: mechanisms and functional assessment[J]. Nat Rev Cardiol, 2015, 12(1):48-62.
[11] Chen C, Wei J, AlBadri A, et al. Coronary microvascular dysfunction-epidemiology, pathogenesis, prognosis, diagnosis, risk factors and therapy[J]. Circ J, 2016, 81(1):3-11.
[12] Crea F, Camici PG, Bairey Merz CN. Coronary microvascular dysfunction: an update[J]. Eur Heart J, 2014, 35(17): 1101-1111.
[13] Shah SJ, Marcus GM, Gerber IL, et al. High-sensitivity C-reactive protein and parameters of left ventricular dysfunction[J]. J Card Fail, 2006, 12(1):61-65.
[14] Matsue Y, Suzuki M, Nagahori W, et al. Endothelial dysfunction measured by peripheral arterial tonometry predicts prognosis in patients with heart failure with preserved ejection fraction[J]. Int J Cardiol, 2013, 168(1):36-40.
[15] Tschope C, Van Linthout S. New insights in(inter)cellular mechanisms by heart failure with preserved ejection fraction[J]. Curr Heart Fail Rep, 2014, 11(4):436-444.
[16] Davis BR, Kostis JB, Simpson LM, et al. Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial[J]. Circulation, 2008, 118(22):2259-2267.
[17] Bajaj NS, Osborne MT, Gupta A, et al. Coronary microvascular dysfunction and cardiovascular risk in obese patients[J]. J Am Coll Cardiol, 2018, 727(7):707-717.
[18] Murthy VL, Naya M, Taqueti VR, et al. Effects of sex on coronary microvascular dysfunction and cardiac outcomes[J]. Circulation, 2014, 129(24):2518-2527.
[19] Nelson MD, Wei J,Bairey Merz CN. Coronary microvascular dysfunction and heart failure with preserved ejection fraction as female-pattern cardiovascular disease: the chicken or the egg?[J]. Eur Heart J, 2018, 39(10):850-852.
[20] Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation[J]. J Am Coll Cardiol, 2013, 62(4):263-271.
[21] Zile MR, Baicu CF, Ikonomidis JS, et al. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin[J]. Circulation, 2015, 131(14):1247-1259.
[22] Mohammed SF, Hussain S, Mirzoyev SA, et al. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction[J]. Circulation, 2015, 131(6):550-559.
[23] Glezeva N,Baugh JA. Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target[J]. Heart Fail Rev, 2014, 19(5):681-694.
[24] Van Tassell BW, Trankle CR, Canada JM, et al. IL-1 blockade in patients with heart failure with preserved ejection fraction[J]. Circ Heart Fail, 2018, 11(8):e005036.
[25] Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure(the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial[J]. Lancet, 2008, 372(9645):1231-1239.
[26] Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial[J]. Lancet, 2012, 380(9851):1387-1395.
[27] Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction[J]. N Engl J Med, 2019, 381(17):1609-1620.
[28] Zinman B, Lachin JM, Inzucchi SE. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes[J]. N Engl J Med, 2016, 374(11):1094.
[29] Neal B, Perkovic V, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes[J]. N Engl J Med, 2017, 377(21):2099.
[30] Dawwas GK, Smith SM,Park H. Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes[J]. Diabetes Obes Metab, 2019, 21(1):28-36.
[31] McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction[J]. N Engl J Med, 2019, 381(21):1995-2008.
[32] Anker SD, Butler J, Filippatos GS, et al. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-preserved trial[J]. Eur J Heart Fail, 2019, 21(10):1279-1287.

备注/Memo

备注/Memo:
基金项目:国家自然科学基金(81473445,91539118,81611130092); 上海市科委优秀学术带头人计划(17XD1405000); 上海市医学领军人才计划(LJRC2015-21)
通信作者:梁春,E-mail:chunliang@smmu.edu.cn
更新日期/Last Update: 2021-01-20